查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2014481

基因改造T細胞市場：2026-2032年全球市場預測（依治療方法、細胞來源、研發階段、應用和最終用戶分類）

Engineered T Cells Market by Therapy Type, Cell Source, Phase, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，工程化 T 細胞市場價值將達到 42.4 億美元，到 2026 年將成長到 52.6 億美元，到 2032 年將達到 224.2 億美元，年複合成長率為 26.82%。

主要市場統計數據
基準年 2025 42.4億美元
預計年份：2026年 52.6億美元
預測年份 2032 224.2億美元
複合年成長率 (%) 26.82%

策略性地引入基因改造 T 細胞，重點關注科學進步、治療潛力、監管變化和相關人員的優先事項。

在基因工程、細胞製造和轉化科學的推動下，基因修飾T細胞療法已從最初的實驗室探索發展成為現代免疫療法的重要支柱。近年來，不僅概念驗證研究取得了進展，平台工程也取得了顯著進步，實現了更精準的標靶化、更強的持久性和更完善的安全性管理。這些進步加速了候選治療方法從臨床前模型向早期和晚期臨床評估的轉化，研發人員的治療目標也從骨髓惡性腫瘤擴展到自體免疫疾病和感染疾病領域。

整體情況基因改造 T 細胞的開發和商業化、突破性治療方法以及將重塑合作生態系統的變革性變化。

在基因修飾T細胞領域，多項相互關聯的變革正在發生，重塑研發模式和商業化路徑。基因編輯、載體設計和細胞製造技術的進步，使得新一代CAR和TCR療法得以實現，這些療法具有更高的特異性、更低的脫靶效應以及模組化的安全開關。同時，生產模式正從單一的學術中心轉向整合式分散生產網路轉變，將集中式品管與在地化生產能力結合。這滿足了個人化療法和現成療法的實際運作需求。

評估美國將於 2025 年實施的關稅措施將如何影響基因改造 T 細胞的供應鏈、零件採購、製造和國際合作。

美國將於2025年實施的關稅措施將為基因改造T細胞計畫的全球供應和營運計算引入新的變數。關稅負擔的變化可能會增加病毒載體、一次性耗材和特殊試劑等關鍵投入品的到貨成本。這將對生產經濟性和產能位置的決策構成壓力。依賴跨境原料分銷和契約製造的贊助公司需要實現供應商多元化，審查緩衝庫存，並重新評估合約條款，以確保專案進度和臨床連續性。

細分市場主導的洞察揭示了治療方法類型、細胞來源、開發階段、臨床應用和最終用戶如何影響研發重點和策略。

在該領域，細分為評估策略、臨床試驗設計和投資決策提供了最有意義的觀點。根據治療方法類型，項目可分為CAR-T和TCR-T療法。每種療法都有其獨特的標靶化框架、生產要求和轉化風險特徵，這些因素會影響適應症的選擇和合作意圖。根據細胞來源，異體移植和自體移植的選擇決定了治療啟動時間、可擴展性、免疫抗原性風險和供應鏈複雜性等因素之間的權衡，這些權衡體現在生產設計和商業化模型中。根據研發階段，研發狀態從臨床前到I期、II期和III期不等，每個階段都有其自身的證據要求、生產規模需求和監管互動，這些因素決定了資源分配和計畫啟動/終止的時機。

美洲、歐洲、中東和非洲以及亞太地區的區域趨勢正在影響臨床試驗活動、策略夥伴關係以及病患取得途徑。

區域趨勢對基因修飾T細胞計畫的開發策略、試驗設計和市場准入計畫有顯著影響。在美洲，由密集的臨床試驗中心、學術機構和專科醫院組成的生態系統支持血液系統惡性腫瘤和某些固體癌治療方案的快速患者招募，而嚴格的安全性和有效性證據在法規核准過程中至關重要。計劃在這些市場推出產品的申辦者必須儘早考慮與支付方的溝通，因為報銷預期和醫院的部署模式會顯著影響商業性可行性和定價策略。與生產和分銷合作夥伴的跨境合作十分普遍，這需要對北美和南美各司法管轄區的物流協調進行周密的規劃。

主要企業概覽，涵蓋研發平台、製造能力、合作模式、臨床管線和商業化重點。

在工程化T細胞領域，公司層面的發展趨勢對競爭定位和合作機會至關重要。領先的研發公司透過CAR架構、TCR發現引擎、基因編輯技術和安全開關等技術平台，以及其專有生產技術的深度和可擴展性來脫穎而出。策略夥伴關係通常涉及擁有獨特生物目標見解的早期創新者與提供後期研發能力、監管經驗和商業基礎設施的大型機構之間的合作。合約研發生產機構（CDMO）也發揮關鍵作用，它們提供模組化解決方案，以加快臨床試驗進程並支持地域擴張。

實際建議：加速實用化，最佳化供應鏈，建立策略夥伴關係，協調監管和報銷方法。

行業領導者應即時採取明確行動，使科學創新與業務和商業性準備相契合。首先，臨床開發計畫應與監管機構和支付方的證據要求保持一致，儘早將生物標記策略、長期追蹤方案和衛生經濟學終點納入試驗設計。這種協調一致可降低後期出現意外事件的風險，並加強對市場價值的討論。其次，應透過對二級供應商進行認證、考慮區域製造地以及在供應商合約中納入關稅和物流方面的緊急條款來增強供應鏈韌性。這些措施將降低外部衝擊帶來的風險，並保障臨床藥物的可靠供應。

透明的調查方法，概述了決策的資料來源、專家參與、分析框架、檢驗程序和研究限制。

支持這些研究發現的研究途徑採用了多維度框架，以確保分析的嚴謹性和實際相關性。研究人員對包括臨床研究人員、生產經理、監管顧問和商業策略師在內的各領域專家進行了結構化訪談，以此作為主要資訊來源，了解實際限制和策略考量。此外，研究人員也透過查閱同儕審查文獻、公開的監管指南、公司資訊披露和臨床試驗註冊資訊等輔助研究資料，對研發管線活動和治療方法進行背景分析。分析架構根據治療方法類型、細胞來源、研發階段、適應症和最終用戶進行細分，突顯了科學創新與實際需求的交會點。

對塑造基因改造 T 細胞療法未來的策略挑戰、科學方法、營運策略和合作模式進行綜合考察。

這些分析綜合起來凸顯了一個明確的挑戰：將基因修飾T細胞的潛力轉化為永續的臨床和商業性成果，需要在生物學、生產製造和市場推廣三個領域同時取得卓越的成就。儘管CAR和TCR工程的科學進步為拓展適應症和改善治療窗口提供了途徑，但如果沒有可擴展、品質保證的生產系統以及能夠滿足支付方和醫療服務提供者期望的有力證據，僅靠技術創新是不夠的。必須預見並納入營運方面的實際情況，避免代價高昂的延誤，這些實際情況包括自體和異體細胞來源的選擇，以及臨床開發每個階段的具體要求，所有這些都應納入專案規劃中。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：依治療方法分類的基因改造T細胞市場

  • CAR T
  • TCR T

第9章：依細胞來源分類的基因改造T細胞市場

  • 同種
  • 本土種植

第10章：基因改造T細胞市場分階段發展

  • 第一階段
  • 第二階段
  • 第三階段
  • 臨床前

第11章：基因改造T細胞市場：依應用領域分類

  • 自體免疫疾病
    • 狼瘡
    • 類風濕性關節炎
  • 感染疾病
  • 腫瘤學
    • 急性淋巴性白血病
    • 非何傑金氏淋巴瘤
    • 固體癌
      • 膠質母細胞瘤
      • 肺癌

第12章 基因改造T細胞市場：依最終用戶分類

  • 醫院
  • 研究機構
  • 專科診所

第13章 基因改造T細胞市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 基因改造T細胞市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 基因改造T細胞市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國基因改造T細胞市場

第17章：中國基因改造T細胞市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Adaptimmune Therapeutics plc
  • Allogene Therapeutics, Inc.
  • Amgen Inc.
  • Atara Biotherapeutics, Inc.
  • Autolus Therapeutics plc
  • bluebird bio, Inc.
  • Bristol-Myers Squibb Company
  • CARsgen Therapeutics Ltd.
  • CRISPR Therapeutics AG
  • Fate Therapeutics, Inc.
  • Gilead Sciences, Inc.
  • Immatics NV
  • Immunocore Limited
  • Lion TCR Pte Ltd.
  • Novartis AG
  • Oxford Biomedica plc
  • Pfizer Inc.
  • Sangamo Therapeutics, Inc.
  • Sorrento Therapeutics, Inc.
  • TCR2 Therapeutics Inc.
Product Code: MRR-4348D129FAA9

The Engineered T Cells Market was valued at USD 4.24 billion in 2025 and is projected to grow to USD 5.26 billion in 2026, with a CAGR of 26.82%, reaching USD 22.42 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 4.24 billion
Estimated Year [2026] USD 5.26 billion
Forecast Year [2032] USD 22.42 billion
CAGR (%) 26.82%

Strategic introduction to engineered T cells emphasizing scientific advances, therapeutic promise, regulatory evolution, and stakeholder priorities

Engineered T cell therapeutics have evolved from a laboratory curiosity into a transformative pillar of modern immunotherapy, driven by advances in genetic engineering, cell manufacturing, and translational science. Recent years have seen progress not only in proof-of-concept studies but also in platform engineering, enabling more precise targeting, improved persistence, and refined safety controls. These improvements have accelerated the movement of candidate therapies from preclinical models into early and later-stage clinical evaluation, and they have broadened the therapeutic ambitions of developers beyond hematologic malignancies to autoimmune and infectious disease applications.

As scientific capabilities mature, stakeholder priorities are shifting in response. Developers must reconcile complex biology with scalable manufacturing and regulatory expectations, while payers and providers increasingly demand evidence of durable benefit and predictable safety. Investors and strategic partners are looking for clarity around differentiating features such as TCR specificity versus CAR modularity, and around cell source decisions between autologous and allogeneic approaches. Against this backdrop, organizational strategies that connect lab innovation to pragmatic clinical pathways and supply chain resilience will determine which programs advance and which stall, making this a pivotal moment for both scientific leadership and pragmatic execution.

Mapping transformative shifts reshaping engineered T cell development, commercial pathways, breakthrough modalities, and collaborative ecosystems

The engineered T cell field is undergoing several interconnected shifts that are redefining development paradigms and commercial pathways. Technological advances in gene editing, vector design, and cell manufacturing are enabling next-generation CAR and TCR approaches with improved specificity, reduced off-target activity, and modular safety switches. At the same time, there is a clear move from single-site academic manufacturing toward integrated yet distributed production networks that blend centralized quality control with local capacity, responding to the operational realities of personalized and off-the-shelf therapies.

Clinical strategy is also changing: developers are increasingly designing trials that embed biomarker-driven patient selection and adaptive endpoints to accelerate readouts while preserving regulatory rigor. Collaborative models between biotechs, large pharma, contract developers, and clinical networks are proliferating, driven by the need to combine discovery agility with late-stage development and commercialization muscle. Meanwhile, reimbursement conversations are moving earlier in development, prompting sponsors to design health economic evidence generation plans alongside clinical protocols. These shifts are reshaping investment criteria, partnership structures, and the competitive landscape, favoring organizations that can simultaneously innovate biologically and execute operationally.

Assessment of how United States 2025 tariffs could reshape engineered T cell supply chains, component sourcing, manufacturing and international collaboration

United States tariff measures implemented in 2025 introduce new variables into the global supply and operational calculus for engineered T cell programs. Changes in tariff exposure can increase the landed cost of critical inputs such as viral vectors, single-use consumables, and specialized reagents, which in turn pressures manufacturing economics and decisions about where to site production capacity. Sponsors that rely on cross-border flows for raw materials or contract manufacturing will need to reassess supplier diversification, buffer inventories, and contractual terms to preserve program timelines and clinical continuity.

In practice, the tariff environment amplifies the importance of near-term supply chain visibility and contingency planning. Organizations will increasingly evaluate the tradeoffs between sourcing lower-cost components from affected geographies versus the flexibility and resiliency provided by alternative suppliers closer to clinical sites. Strategic responses include renegotiating supplier agreements to allocate tariff risk, qualifying secondary suppliers in tariff-stable jurisdictions, and accelerating technology transfer to alternate manufacturing partners. Regulatory filings and clinical timelines may require adjustment to reflect these operational changes, and commercial launch planning must incorporate revised cost structures and distribution implications. Overall, tariff shifts highlight the need for integrated planning across procurement, manufacturing, regulatory affairs, and commercial teams to maintain program momentum.

Segment-driven insights revealing how therapy types, cell sources, development phases, clinical applications, and end users shape R&D focus and strategy

Segmentation provides the lens through which strategy, clinical design, and investment decisions are most meaningfully assessed in this domain. Based on Therapy Type, programs divide between CAR T and TCR T approaches, each with distinct targeting frameworks, manufacturing requirements, and translational risk profiles, which influence indication focus and partnering interest. Based on Cell Source, decisions between Allogeneic and Autologous approaches determine tradeoffs among time to treatment, scalability, immunogenicity risk, and supply chain complexity, and they inform manufacturing design and commercialization models. Based on Phase, development status ranges from Preclinical to Phase I, Phase II, and Phase III, with each stage presenting unique evidence requirements, manufacturing scale demands, and regulatory interactions that shape resource allocation and go/no-go timing.

Based on Application, therapeutic ambitions extend across Oncology, Infectious Diseases, and Autoimmune Diseases. The Oncology category includes hematologic indications such as Acute Lymphoblastic Leukemia and Non-Hodgkin Lymphoma, as well as Solid Tumor programs targeting Glioblastoma and Lung Cancer, each presenting different tumor microenvironment challenges and delivery considerations. The Autoimmune Diseases segment further explores indications such as Lupus and Rheumatoid Arthritis, where long-term immune modulation and safety profiles require distinct trial designs. Based on End User, deployment contexts span Hospitals, Research Institutes, and Specialty Clinics, and these end users dictate logistics, in-hospital treatment pathways, and post-treatment monitoring frameworks. Together, these segmentation dimensions reveal where scientific opportunity aligns with operational capability and commercial access potential.

Regional dynamics across the Americas, EMEA, and Asia-Pacific that shape clinical trial activity, strategic partnerships, and patient access approaches

Regional dynamics materially influence development strategy, trial design, and access planning for engineered T cell programs. In the Americas, a dense ecosystem of clinical trial sites, academic centers, and specialized hospitals supports rapid patient accrual for hematologic and select solid tumor protocols, while regulatory pathways emphasize rigorous safety and efficacy evidence. Sponsors intending to launch in these markets must consider payer engagement earlier, as reimbursement expectations and hospital adoption patterns will shape commercial viability and pricing strategy. Cross-border collaborations with manufacturing and distribution partners are common, and logistical coordination across North and South American jurisdictions requires careful planning.

In EMEA, regulatory harmonization and clinical networks offer advantages for multicenter studies, but variations in national reimbursement and health technology assessment processes require tailored value demonstration strategies. Capacity constraints at transplantation and specialized cell therapy centers can influence site selection and operational timelines. In Asia-Pacific, there is a growing clinical and manufacturing footprint with strong public and private investment in advanced therapies, and adaptive regulatory initiatives in several markets can expedite local development and market entry. However, regional intellectual property considerations, local partnering norms, and differing healthcare delivery models require sponsors to adapt clinical, regulatory, and commercialization approaches to each submarket. Understanding these regional nuances is essential to align clinical development, manufacturing footprints, and market access plans.

Profiles of leading companies highlighting R&D platforms, manufacturing capabilities, partnership models, clinical pipelines, and commercialization priorities

Company-level dynamics are central to competitive positioning and partnership opportunities across the engineered T cell landscape. Leading developers are differentiating by technological platform-whether in CAR architecture, TCR discovery engines, gene editing methods, or safety switch implementations-and by the depth of their proprietary manufacturing know-how and scale capabilities. Strategic partnerships frequently pair early-stage innovators that hold unique targeting biology with larger organizations that provide late-stage development capacity, regulatory experience, and commercial infrastructure. Contract development and manufacturing organizations also play a pivotal role, offering modular solutions to reduce time to clinic and to support geographic expansion.

Investors and potential partners evaluate companies on a combination of scientific differentiation, clinical evidence progression across phases, supply chain robustness, and the clarity of commercialization pathways for target indications. Companies that articulate a compelling translational rationale, backed by reproducible manufacturing processes and an evidence generation plan addressing both clinical outcomes and health economic endpoints, are most likely to secure strategic collaborations and downstream commercial opportunities. Operational execution-ranging from vector supply to site training and long-term follow-up mechanisms-remains a critical determinant of whether scientific promise converts into sustainable therapeutic programs.

Practical recommendations for leaders to speed translation, optimize supply chains, forge strategic partnerships, and align regulatory/reimbursement approaches

Industry leaders should take immediate, prioritized actions to bridge scientific innovation with operational and commercial readiness. First, align clinical development plans with evidence needs of regulators and payers by integrating biomarker strategies, long-term follow-up protocols, and health economic endpoints into trial designs early. This alignment reduces the risk of later-stage surprises and strengthens value conversations at launch. Second, build supply chain resilience by qualifying secondary suppliers, exploring regional manufacturing hubs, and negotiating supplier contracts that include tariff and logistics contingencies. These measures reduce exposure to external shocks and support reliable clinical supply.

Third, pursue partnership models that complement internal capabilities: consider risk-sharing and co-development structures with partners that bring regulatory and commercialization scale, while preserving optionality for lead asset development. Fourth, invest in manufacturing transferability and quality systems that enable reproducible processes across sites, thereby reducing time to clinic and supporting broader geographic rollout. Finally, create cross-functional governance that connects R&D, manufacturing, regulatory affairs, and commercial teams to ensure coordinated decision-making on clinical prioritization, evidence generation, and market access strategies. These steps will enable organizations to convert program potential into measurable clinical and commercial outcomes.

Transparent research methodology outlining data sources, expert engagements, analytical frameworks, validation steps, and study limitations for decision-making

The research approach underpinning these insights combined a multi-method framework to ensure analytical rigor and practical relevance. Primary inputs included structured interviews with subject matter experts spanning clinical investigators, manufacturing leads, regulatory advisors, and commercial strategists to capture real-world operational constraints and strategic considerations. Secondary research reviewed peer-reviewed literature, publicly available regulatory guidance, company disclosures, and clinical trial registries to contextualize pipeline activity and therapeutic approaches. Analytical frameworks incorporated segmentation by therapy type, cell source, development phase, application, and end user to map where scientific innovation intersects with operational demand.

Validation steps included cross-checking expert statements against publicly disclosed trial and regulatory milestones, and synthesizing patterns across multiple data sources to mitigate single-source bias. Study limitations are acknowledged: proprietary commercial agreements and confidential development programs may not be fully reflected, and emerging technologies can evolve rapidly, which necessitates ongoing monitoring. Nevertheless, the combination of expert engagement, evidence triangulation, and structured analytical lenses provides a robust foundation for strategic planning and decision-making.

Concluding synthesis of strategic imperatives, scientific pathways, operations, and collaborative models shaping the future of engineered T cell therapeutics

The cumulative analysis highlights a clear imperative: converting engineered T cell promise into durable clinical and commercial impact requires simultaneous excellence in biology, manufacturing, and market execution. Scientific advances in CAR and TCR engineering offer pathways to expanded indications and improved therapeutic windows, but technical novelty alone is insufficient without scalable, quality-assured manufacturing and compelling evidence that addresses payer and provider expectations. Operational realities-from cell sourcing choices between autologous and allogeneic options to the phase-specific demands of clinical development-must be anticipated and integrated into program planning to avoid costly delays.

Collaborative models that pair nimble scientific organizations with partners that offer development scale and access capabilities will continue to dominate successful pathways to market. Regionally informed strategies are essential, as regulatory, clinical capacity, and reimbursement conditions vary across the Americas, EMEA, and Asia-Pacific. By aligning translational science with pragmatic operational planning and early payer engagement, stakeholders can increase the probability that engineered T cell innovations reach patients and sustain commercial viability. The path forward rewards integrated thinking and disciplined execution across the entire value chain.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Engineered T Cells Market, by Therapy Type

  • 8.1. CAR T
  • 8.2. TCR T

9. Engineered T Cells Market, by Cell Source

  • 9.1. Allogeneic
  • 9.2. Autologous

10. Engineered T Cells Market, by Phase

  • 10.1. Phase I
  • 10.2. Phase Ii
  • 10.3. Phase Iii
  • 10.4. Preclinical

11. Engineered T Cells Market, by Application

  • 11.1. Autoimmune Diseases
    • 11.1.1. Lupus
    • 11.1.2. Rheumatoid Arthritis
  • 11.2. Infectious Diseases
  • 11.3. Oncology
    • 11.3.1. Acute Lymphoblastic Leukemia
    • 11.3.2. Non Hodgkin Lymphoma
    • 11.3.3. Solid Tumor
      • 11.3.3.1. Glioblastoma
      • 11.3.3.2. Lung Cancer

12. Engineered T Cells Market, by End User

  • 12.1. Hospital
  • 12.2. Research Institutes
  • 12.3. Specialty Clinics

13. Engineered T Cells Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Engineered T Cells Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Engineered T Cells Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Engineered T Cells Market

17. China Engineered T Cells Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Adaptimmune Therapeutics plc
  • 18.6. Allogene Therapeutics, Inc.
  • 18.7. Amgen Inc.
  • 18.8. Atara Biotherapeutics, Inc.
  • 18.9. Autolus Therapeutics plc
  • 18.10. bluebird bio, Inc.
  • 18.11. Bristol-Myers Squibb Company
  • 18.12. CARsgen Therapeutics Ltd.
  • 18.13. CRISPR Therapeutics AG
  • 18.14. Fate Therapeutics, Inc.
  • 18.15. Gilead Sciences, Inc.
  • 18.16. Immatics N.V.
  • 18.17. Immunocore Limited
  • 18.18. Lion TCR Pte Ltd.
  • 18.19. Novartis AG
  • 18.20. Oxford Biomedica plc
  • 18.21. Pfizer Inc.
  • 18.22. Sangamo Therapeutics, Inc.
  • 18.23. Sorrento Therapeutics, Inc.
  • 18.24. TCR2 Therapeutics Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ENGINEERED T CELLS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ENGINEERED T CELLS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ENGINEERED T CELLS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES ENGINEERED T CELLS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA ENGINEERED T CELLS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ENGINEERED T CELLS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY CAR T, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY CAR T, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY CAR T, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY TCR T, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY TCR T, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY TCR T, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY ALLOGENEIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY ALLOGENEIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY ALLOGENEIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY AUTOLOGOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY AUTOLOGOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY AUTOLOGOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY PHASE I, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY PHASE I, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY PHASE I, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY PHASE II, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY PHASE II, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY PHASE II, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY PHASE III, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY PHASE III, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY PHASE III, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY PRECLINICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY PRECLINICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY PRECLINICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY LUPUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY LUPUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY LUPUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY NON HODGKIN LYMPHOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY NON HODGKIN LYMPHOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY NON HODGKIN LYMPHOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY GLIOBLASTOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY GLIOBLASTOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY GLIOBLASTOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS ENGINEERED T CELLS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS ENGINEERED T CELLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA ENGINEERED T CELLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA ENGINEERED T CELLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA ENGINEERED T CELLS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA ENGINEERED T CELLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE ENGINEERED T CELLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST ENGINEERED T CELLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA ENGINEERED T CELLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC ENGINEERED T CELLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 152. ASEAN ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN ENGINEERED T CELLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. GCC ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. GCC ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. GCC ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 159. GCC ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2018-2032 (USD MILLION)
  • TABLE 160. GCC ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 161. GCC ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 162. GCC ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 163. GCC ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2018-2032 (USD MILLION)
  • TABLE 164. GCC ENGINEERED T CELLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION ENGINEERED T CELLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2018-2032 (USD MILLION)
  • TABLE 182. BRICS ENGINEERED T CELLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 183. G7 ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. G7 ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. G7 ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 186. G7 ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2018-2032 (USD MILLION)
  • TABLE 187. G7 ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 188. G7 ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 189. G7 ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 190. G7 ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2018-2032 (USD MILLION)
  • TABLE 191. G7 ENGINEERED T CELLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. NATO ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. NATO ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. NATO ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 195. NATO ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2018-2032 (USD MILLION)
  • TABLE 196. NATO ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 197. NATO ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 198. NATO ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 199. NATO ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2018-2032 (USD MILLION)
  • TABLE 200. NATO ENGINEERED T CELLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES ENGINEERED T CELLS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED STATES ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED STATES ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED STATES ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2018-2032 (USD MILLION)
  • TABLE 210. UNITED STATES ENGINEERED T CELLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 211. CHINA ENGINEERED T CELLS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 212. CHINA ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. CHINA ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 214. CHINA ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2018-2032 (USD MILLION)
  • TABLE 215. CHINA ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 216. CHINA ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 217. CHINA ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 218. CHINA ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2018-2032 (USD MILLION)
  • TABLE 219. CHINA ENGINEERED T CELLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)